InspireMD Reports Strong Q4 and Full Year 2025 Results: Substantial Revenue Growth, U.S. Momentum, and 2026 Outlook
Key Highlights from InspireMD’s 2025 Financial Report
- Q4 2025 revenue surged 62% year-over-year to \$3.1 million, driven by robust commercial traction in the U.S. and growing international demand.
- Full year 2025 revenue rose 28% to \$9.0 million.
- Gross profit margin improved notably, reflecting a favorable sales mix toward higher-margin U.S. revenues.
- Significant operational investments, particularly in U.S. commercial infrastructure and headcount, contributed to increased operating expenses.
- Net loss widened to \$48.8 million for 2025 (versus \$32.0 million in 2024), primarily due to scaling commercial activities.
- Cash and marketable securities at year-end 2025 stood at \$54.2 million, up from \$34.6 million a year earlier, bolstering liquidity.
- 2026 revenue guidance: \$13–15 million, representing anticipated growth of 45–65% versus 2025.
Business and Regulatory Developments
- U.S. Commercial Launch: InspireMD’s CGuard® Prime carotid stent system demonstrated sustained traction in the U.S. since its launch, with over 500 cumulative carotid procedures performed across leading hospitals and integrated delivery networks.
- Clinical Progress: Completed enrollment of the CGUARDIANS II pivotal trial, evaluating CGuard Prime for transcarotid artery revascularization (TCAR). The results manuscript was published in the Journal of the American College of Cardiology, underscoring clinical credibility.
- Regulatory Milestone: Submission of a PMA-S (Premarket Approval Supplement) to the U.S. FDA, seeking expanded indications for CGuard Prime in TCAR procedures—a move that could potentially double the U.S. addressable market if approved.
Financial Details and Trends
- Q4 2025 Revenue: \$3.1 million, up 62% year-over-year and 25% sequentially. U.S. revenue contributed \$0.9 million, growing 74% sequentially in its second quarter of launch. International revenue reached \$2.3 million, up 17% year-over-year.
- Gross Profit: Q4 2025 gross profit was \$1.2 million (37.5% of revenue), significantly higher than \$0.5 million (24.1%) in Q4 2024, driven by the U.S. sales mix.
- Operating Expenses: Rose to \$13.3 million in Q4 2025 (versus \$9.8 million in Q4 2024), and \$52.3 million for the full year (up from \$35.0 million). The increase reflects scaling of the U.S. commercial team and infrastructure investments.
- Financial Income: Net financial income for Q4 2025 was \$0.4 million, slightly higher year-over-year due to marketable securities and money market returns, partially offset by adverse exchange rate movements.
- Net Loss: Q4 2025 net loss was \$11.8 million (\$0.14 per share), versus \$9.2 million (\$0.19 per share) in Q4 2024. Full-year net loss was \$48.8 million (\$0.76 per share), compared to \$32.0 million (\$0.76 per share) in 2024.
- Balance Sheet: Cash and equivalents plus marketable securities totaled \$54.2 million at year-end 2025, supporting continued operations and expansion plans.
2026 Outlook and Guidance
InspireMD has issued its first revenue guidance for 2026, targeting \$13–15 million, which equates to a 45–65% increase over 2025. This signals continued momentum from the U.S. launch and anticipated regulatory and clinical catalysts, particularly the potential FDA approval for TCAR indication, which management states could double the U.S. addressable market. Investors should note that this guidance is subject to multiple execution and regulatory risks, and actual results could vary materially.
Potential Shareholder Impact and Price Sensitive Items
- Strong revenue growth and improving gross margins signal successful execution of U.S. commercialization, which may positively influence investor sentiment and share value.
- The ongoing U.S. commercial rollout and PMA-S submission for TCAR indication are critical catalysts. FDA approval could significantly expand the market and accelerate growth—this is a key item for shareholders to monitor.
- Substantial operating losses and increased expenses reflect high investment phase, which, while building a foundation for future growth, also increases execution risk. The company’s ability to transition to profitability will be closely watched.
- Strong cash position (\$54.2 million at 2025 year-end) reduces near-term liquidity risk, supporting continued investment in commercialization and R&D.
- 2026 revenue guidance is ambitious, and management’s confidence in accelerating growth may support positive share price momentum if execution remains on track.
Risks and Forward-Looking Statements
InspireMD’s forward-looking statements are subject to numerous risks, including but not limited to: continued losses and negative cash flow, need for additional capital, regulatory and clinical trial uncertainties, competition, manufacturing risks, reimbursement challenges, and international operational risks. Shareholders should consult the company’s filings, particularly the “Risk Factors” section in the 2025 Form 10-K, for a comprehensive understanding of the company’s risk profile.
Conclusion
InspireMD’s 2025 financial report highlights strong revenue growth, improving margins, and a strategy focused on U.S. market expansion and clinical differentiation. The company’s 2026 outlook, pending regulatory milestones, and expanding commercial footprint present both significant opportunities and risks for shareholders. The next 12 months will be pivotal, with the FDA’s decision on the TCAR indication and execution of the commercial strategy in focus.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult financial professionals before making investment decisions. All forward-looking statements are subject to risks and uncertainties as detailed in InspireMD’s SEC filings.
View InspireMD, Inc. Historical chart here
